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OBJECTIVES: Nosocomial pneumonia (NP) is a costly and life-
threatening complication of hospitalized patients. This study
assesses the outcomes and costs associated with NP, speciﬁcally
those with mechanical ventilation (MV) from the Belgian hospi-
tal perspective. METHODS: Data from the Belgian minimum
basic data set from the ﬁrst half of 2004 was used for this study.
Patients from 37 hospitals with an ICD-9-CM code of bacterial
pneumonia (481.xx–482.xx) and at least one IV antibiotic
administration during their hospital stay were extracted. To
isolate cases of pneumonia that were likely to be nosocomial,
those with a secondary diagnosis of pneumonia and planned
(versus emergency) admissions were retained. Outcomes for
patients categorized on the basis of ICU stay and use of MV were
assessed. Costs from the Belgian payer perspective were applied
to resources utilized. RESULTS: The ﬁnal analytical sample con-
tained 441 admissions; 115 (26%) with an ICU stay and MV
(ICU+MV), 47 (11%) with an ICU stay without MV (ICU Non-
MV) and 279 (63%) without ICU or MV (Non-ICU Non-MV).
Approximately 74% were at least 65 years and 66% were males.
Median length of hospital stay for the ICU+MV, ICU Non-MV
and Non-ICU Non-MV groups were 32, 30, and 16 days. Total
median hospital costs were €22,240, €14,565 and €14,793 for
ICU+MV, ICU Non-MV and Non-ICU Non-MV respectively.
Antibiotics formed a small part of the total cost: €972, €671,
and €453 for ICU+MV, ICU Non-MV and Non-ICU Non-MV
respectively. The ICU+MV group had the highest mortality
(40%) compared to ICU Non-MV (26%) and Non-ICU Non-
MV (24%). CONCLUSIONS: NP is a costly complication, with
high mortality risks, speciﬁcally for patients with MV. This dif-
ference may be in part attributable to underlying pathogen dif-
ferences, patient and pneumonia severity, or the appropriateness
of anti-infective treatment choice. Further investigation is war-
ranted to investigate the inﬂuence of these factors.
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COST-BENEFIT ANALYSIS OF VACCINATION PROGRAMME
AGAINST POLIOMYELITIS IN MALAYSIA: ORAL POLIO
VACCINE (OPV) VS INACTIVATED POLIO VACCINE (IPV)
Aljunid S
National University of Malaysia, Kuala Lumpur, Malaysia
OBJECTIVES: To conduct a cost-beneﬁt analysis of switching
from the current regime using combination of DTwcPHib + OPV
to new combined vaccine DTwcPHib + IPV (Stand alone) and
DTacPHibIPV (Pentavalent combination). METHODS: Incre-
mental cost-beneﬁt approach was used in the methodology. Cost
of the vaccination programmes includes price of vaccines, cost
of vaccine wastage, cost of transportation and maintenance of
cold chain, cost of vaccines administration and cost of manag-
ing adverse events. The beneﬁts measured in this study are cost
of avoiding Vaccine Associated Paralytic Polio (VAPP) and other
adverse events such as mild fever, high fever and convulsions. A
time-motion survey was conducted in one government health
centre to obtain the human resource cost of vaccine administra-
tion. Cost of VAPP was estimated from an expert group discus-
sion while the cost of other adverse events (high fever and mild
fever) was obtained from interviews with 400 mothers and chil-
dren attending three government clinics. RESULTS: The current
program at the cost of RM 32.83 per dose of DTwcPHib + OPV
vaccine would cost the country of RM 60.43 million annually.
At RM 46.40 per dose of DTwcPHib + IPV (Stand alone), the
total cost of program would incur RM85.42 million and at RM
40.19 per dose of the DTacPHibIPV (Pentavalent combination),
the total cost of program was RM73.99 million. Incremental
cost-beneﬁt ratio when switching from current programme to
DTwcPHib + IPV cost is only 0.0012. However, switching from
current programme to DTacPHibIPV will lead beneﬁt to out-
weigh cost by 15 times. Sensitivity analysis done showed that the
cost-beneﬁt ratio ranges between 8.2 and 9.7 for the best and
worst case scenario respectively. CONCLUSIONS: Switching
from the current programme to DTacPHib IPV (Pentavalent
combination) is highly cost-beneﬁcial and should be the pre-
ferred option in the strategy to change from OPV to IPV in vac-
cination programme against poliomyelitis.
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OBJECTIVES: To summarize treatment management and clini-
cal outcomes patterns in patients with multi-drug-resistant
Staphylococcus aureus infections (MRSAs), from the experiences
of selected Canadian infectious diseases specialists. METHODS:
A panel of specialists from Canadian teaching hospitals was sur-
veyed to collect data on physician demographics and their typical
management of MRSA infected patients. Descriptive statistics
were calculated. RESULTS: At the interim point, eleven of 31
physicians (35%) had participated. All physicians reported
having access (full or restricted) to antibiotics with activity
against MRSA regardless of formulary status. Of those agents,
vancomycin was listed on all hospital formularies, followed by
linezolid (91%) and quinupristin+dalfopristin (27%). On
average, 156 (SD = 147) MRSA patients were admitted annually
to their units, with 56% (SD = 23%) reported as nosocomial
infections. The most commonly reported sites of infection were
skin/soft tissue (31%, SD = 10%), and bacteremia/septicemia
(29%, SD = 12%). According to 91% of the physician panel,
patients received treatment if MRSA was suspected in 37% of
cases and the remainder when conﬁrmed. Vancomycin was the
most commonly used ﬁrst line treatment (100%). Linezolid was
most often used as second line treatment (50%). On average,
81% (SD = 16%) of patients with MRSA were treated with
monotherapy. Most common combinations were vancomycin+
rifampin and vancomycin+ciproﬂoxacin. On average, 52% (SD
= 22%) of patients with nosocomial infections had their infec-
tions resolved while in hospital. MRSA infections were resolved
in an average of 16.6 (SD = 6.0) days from diagnosis and the
average length of stay in hospital was 14.6 (SD = 4.0) days.
When MSRA infections were not resolved in hospital, the attrib-
utable mortality rate was 16%. CONCLUSIONS: Although
physicians typically have access to treatments for MRSA, high
mortality and prolonged length of stay were observed. Further
research is warranted to determine if clinical considerations for
empiric treatment may improve patient outcomes.
